Pan‐cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response.

This article presents a study on tumour endothelial cells (TECs) and their role in tumour development and angiogenesis. The researchers created a pan-cancer TEC atlas using single-cell sequencing data from 381 samples. They identified different clusters of TECs and found that angiogenic components were elevated in tumours compared to normal endothelial cells. They also discovered two novel tip EC clusters, INSR+ tip ECs and PGF+ tip ECs, which were associated with angiogenesis. The study provides valuable insights into the mechanisms of tumour angiogenesis and suggests potential antiangiogenic targets for future therapies. Additionally, the article discusses the role of the insulin receptor (INSR) in angiogenesis, specifically in tumor endothelial cells (TECs). The study found that INSR is expressed exclusively in tumor ECs and is correlated with classical EC markers in multiple cancers, indicating its role as an angiogenic marker. In vitro and in vivo experiments demonstrated that INSR enhances angiogenic capacity, making it a promising antiangiogenic target. Furthermore, the study found that mature venous ECs expressing MHC-II molecules are associated with a better response to immunotherapy. The findings contribute to the development of innovative antiangiogenic agents. [Extracted from the article]